|SBBP -- USA Stock|| |
USD 6.75 0.55 8.87%
Founder and Sr. Clinical Advisor
We currently do not have informatin regarding Per MD. This executive tanure with Strongbridge Biopharma plc is not currenlty determined.
The company has return on total asset (ROA)
of (25.16) %
which means that it has lost $25.16 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE)
of (556.52) %
meaning that it created substantial loss on money invested by shareholders.
The company currently holds 76.14 M in liabilities. Strongbridge Biopharma plc has Current Ratio of 8.71 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.
Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs. Strongbridge Biopharma plc was founded in 1996 and is headquartered in Trevose, Pennsylvania. Strongbridge Biopharma operates under Biotechnology classification in USA and traded on NASDAQ. It employs 66 people.Strongbridge Biopharma plc (SBBP) is traded on NASDAQ in USA. It is located in PENNSYLVANIA, U.S.A and employs 66 people. Strongbridge Biopharma is listed under Pharmaceutical Products category by Fama And French industry classification.
Strongbridge Biopharma Leadership Team
|Matthew Pauls, CEO, MBA|
|Brian Davis, CFO, MBA|
|Richard Kollender, Director|
|Davis, CFO, MBA|
|Robert Lutz, Executive, MBA|
|Garheng Kong, Director, MBA|
|John Johnson, Chairman|
|Marten Steen, Director, Ph.D|
|Stephen Long, Executive|
|Ruth MD, Executive|
|Ruth ThieroffEkerdt, Executive, Ph.D|
|Hilde Steineger, Director, Ph.D|
|Per MD, Founder|
Stock Performance Indicators